These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36330389)

  • 1. Identification and validation of a 9-gene signature for the prognosis of ovarian cancer by integrated bioinformatical analysis.
    Chen S; Yang M; Yang H; Tang Q; Gu C; Wei W
    Ann Transl Med; 2022 Oct; 10(19):1059. PubMed ID: 36330389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
    Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
    J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer.
    Jiang H; Awuti G; Guo X
    ACS Omega; 2023 Sep; 8(36):33017-33031. PubMed ID: 37720747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
    Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer.
    Feng J; Yu Y; Yin W; Qian S
    J Ovarian Res; 2023 Feb; 16(1):31. PubMed ID: 36739404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of a Nine-Gene Signature Related to Tumor Microenvironment in Lung Adenocarcinoma.
    Zhong H; Wang J; Zhu Y; Shen Y
    Front Cell Dev Biol; 2021; 9():700607. PubMed ID: 34540825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
    Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
    J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma.
    Yue C; Ma H; Zhou Y
    PeerJ; 2019; 7():e8128. PubMed ID: 31803536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
    Liu J; Liu Y; Yang C; Liu J; Hao J
    Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A ferroptosis-related lncRNA signature predicts prognosis in ovarian cancer patients.
    Peng J; Hao Y; Rao B; Zhang Z
    Transl Cancer Res; 2021 Nov; 10(11):4802-4816. PubMed ID: 35116333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms.
    Yuan Q; Ren J; Wang Z; Ji L; Deng D; Shang D
    Front Genet; 2021; 12():692953. PubMed ID: 34490033
    [No Abstract]   [Full Text] [Related]  

  • 15. Development and Validation of a Hypoxia-related Prognostic Model for Ovarian Cancer.
    Xie L; Pan M; Zhang Z; Jiang X; Chen Y; Liu G; Chen Y; Zeng Y; Guan J; Lu R; Zeng L
    Recent Pat Anticancer Drug Discov; 2022; 18(2):161-173. PubMed ID: 35747984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
    Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z
    Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Validation of Angiogenesis-Related Gene Expression for Predicting Prognosis in Patients With Ovarian Cancer.
    Wang Y; Li BX; Li X
    Front Oncol; 2021; 11():783666. PubMed ID: 35047401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and validation of a transcription factors-based prognostic signature for ovarian cancer.
    Cheng Q; Li L; Yu M
    J Ovarian Res; 2022 Feb; 15(1):29. PubMed ID: 35227285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of an eight-gene signature based predictive model to evaluate the prognosis of hepatocellular carcinoma patients: a bioinformatic study.
    Zhang J; Fu X; Zhang N; Wang W; Liu H; Jia Y; Nie Y
    Ann Transl Med; 2022 May; 10(9):524. PubMed ID: 35928748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.